CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Nature
Abstract
The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.
Description
Keywords
Antigens, cd19, Antigens, neoplasm, Biomarkers, tumor, Clinical trials as topic, Genetic engineering, Humans, Immunotherapy, adoptive, Leukemia, b-cell, Lymphoma, b-cell, Receptors, chimeric antigen, T-lymphocytes, Treatment outcome, Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine, Lisocabtagene maraleucel, Tisagenlecleucel t, Tocilizumab, Cd19 antigen, Cd19 molecule, human, Tumor antigen, Tumor marker, Acute lymphoblastic leukemia, B cell leukemia, B cell lymphoma, Cancer survival, Chimeric antigen receptor t-cell immunotherapy, Diffuse large b cell lymphoma, Drug efficacy, Evidence based medicine, Human, Large cell lymphoma, Lymphocytic lymphoma, Neurotoxicity, Nonhodgkin lymphoma, Overall survival, Physician, Priority journal, Progression free survival, Review, Adoptive immunotherapy, Adverse event, Clinical trial (topic), Genetics, Immunology, Metabolism, Mortality, Procedures, T lymphocyte